CLYMClimb Bio, Inc.同业对比
Climb Bio, Inc. 与SIC 2834 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CLYM本股 | $694M#9 | — | 4.7x#10 | — | — | 19.0%#4 | — | -40.4%#5 | — | — | 702.6%#1 | — |
| AAPG | $7.1B#4 | — | — | — | — | — | — | — | — | — | -52.5%#12 | — |
| AARD | $117M#12 | — | 1.3x#3 | — | — | -179.7%#11 | — | -66.2%#8 | — | — | -58.3%#13 | — |
| ABBV | $465.8B#1 | 129.9x#5 | — | 7.6x#3 | 8.6%#5 | -1.2%#8 | 24.6%#1 | — | 20.0%#1 | — | 41.3%#4 | 2.5%#1 |
| ABCL | $1.6B#6 | — | 1.8x#4 | 21.9x#4 | 160.6%#1 | 10.1%#5 | -289.0%#5 | -15.6%#4 | -25.2%#4 | — | — | — |
| ABEO | $356M#10 | 6.6x#2 | 2.5x#6 | 61.1x#6 | — | -211.7%#12 | -1536.9%#7 | -49.1%#7 | -101.1%#7 | — | -7.6%#9 | — |
| ABT | $188.3B#2 | 30.3x#4 | 3.6x#9 | 4.2x#2 | 5.7%#6 | -51.3%#9 | 18.2%#2 | 12.5%#2 | 8.3%#3 | — | -13.8%#10 | 2.2%#2 |
| ABUS | $845M#7 | 5.2x#1 | 3.2x#7 | 60.0x#5 | 128.2%#2 | 52.1%#2 | -271.0%#4 | -12.9%#3 | — | — | 29.3%#5 | — |
| ABVC | $26M#15 | — | 2.4x#5 | 88.7x#7 | 48.0%#3 | -61.3%#10 | -2416.0%#8 | -73.4%#9 | -65.9%#6 | — | -66.0%#14 | — |
| ABVX | $9.3B#3 | — | — | — | — | — | — | — | — | — | 69.5%#3 | — |
| ACAD | $4.5B#5 | 11.9x#3 | 3.6x#8 | 4.2x#1 | 11.9%#4 | 73.0%#1 | 9.8%#3 | 31.3%#1 | 10.9%#2 | — | 16.4%#6 | — |
| ACET | $77M#13 | — | 0.6x#1 | — | — | 0.3%#7 | — | -83.4%#11 | — | — | -26.7%#11 | — |
| ACIU | $231M#11 | — | — | — | — | — | — | — | — | — | -0.7%#8 | — |
| ACRS | $715M#8 | — | 5.0x#11 | 91.4x#8 | -58.2%#7 | 50.8%#3 | -975.9%#6 | -45.2%#6 | -60.8%#5 | 3#1 | 229.3%#2 | — |
| ACRV | $61M#14 | — | 0.6x#2 | — | — | 3.3%#6 | — | -81.6%#10 | — | — | 6.8%#7 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-07-30。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议